Entest BioMedical files third patent application

A third patent application was recently filed by Entest BioMedical Inc. (OTC Bulletin Board: ENTB) in concern to COPD (chronic obstructive pulmonary disease).

COPD is believed to affect more than 5 million people in the United States alone and claims around 120,000 deaths every year.

It is important to note here that a recent article "Immunologic aspects of chronic obstructive pulmonary disease" by Cosio et al in the June 4th, 2009 issue of New England Medical Journal had suggested that COPD is not just a disease of inflammation but more of an active immunological attack.

From News-Medical.Net:

"To date Entest has filed two previous patent applications covering use of fat stem cell components in COPD and methods of using photoceuticals to enhance stem cell therapy. The current patent application has a variety of derivative uses outside of COPD including treatment of transplantation rejection, and other disease in which the immune system has gone awry," stated David Koos, Entest's CEO.

The essence of the technology is the use of existing implantable devices to deliver chemical/protein signals that specifically stop inflammatory reactions in a manner that is more in tune with biological processes. Instead of us "telling the body" what it should do with a blunt-force approach, as is the standard of care, the current invention uses more natural and slow acting interventions.

Dr. Stephen Josephs, inventor of the technology, said that significance of the inflammatory process in COPD is exemplified by use of broad-acting steroids used to reduce inflammation but they can bring adverse effects.